Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.70 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.60 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.60 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.55 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9366741 | 0.98 | CYP1A2 (0.96) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL9366928 | 0.89 | CYP2D6 (0.79) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL9366991 | 0.89 | CYP1A2 (0.79) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL29766950 | 0.89 | CYP1A2 (0.79) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL29154466 | 0.89 | CYP1A2 (0.79) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| Fumaric Acid SCHEMBL467224 | 0.88 | CYP1A2 (0.77) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| Maleic Acid SCHEMBL467223 | 0.88 | CYP1A2 (0.77) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL10317634 | 0.86 | CYP1A2 (0.76) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL16225987 | 0.85 | CYP1A2 (0.72) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR | |
| SCHEMBL9366750 | 0.85 | CYP1A2 (0.72) | CYP1A2CYP2C19CYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12539337-B2 | Nanostructure conjugates for modulation of location-specific subtypes of receptors and ion channels | Molokanova, Elena (US) | 2026-02-03 | — | — | US | claimed |
| US-20230355596-A1 | COMPOSITIONS AND METHODS OF USING NMDAR INHIBITORS AND KINASE INHIBITORS TO TREAT LIVER CANCER | VERSITECH LIMITED (CN) | 2023-11-09 | — | — | US | claimed |
| WO-2010101649-A2 | SIGMA 1 RECEPTOR INHIBITION AS A NOVEL THERAPEUTICAL APPROACH AGAINST HEPATITIS C VIRUS INFECTION | GASTAMINZA PABLO (US) | 2010-09-10 | — | — | WO | claimed |
| EP-1773306-A1 | MEDICAMENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Greenpharma (FR) | 2007-04-18 | — | — | EP | claimed |
| WO-2006018538-A1 | MEDICAMENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | GREENPHARMA (FR) | 2006-02-23 | — | — | WO | claimed |
| EP-0346791-B1 | 1,2-diarylethylamines for treatment of neurotoxic injury | SEARLE & CO (US) | 1994-04-06 | — | — | EP | claimed |
| EP-0346791-A1 | 1,2-diarylethylamines for treatment of neurotoxic injury | G.D. Searle & Co. (US) | 1989-12-20 | — | — | EP | claimed |
| JP-2036171-A | — | — | None | — | — | JP | disclosed |
| US-12636264-B2 | Methods and materials for diagnosis and treatment of neuronal disorder | GENEMO, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12539337-B2 | Nanostructure conjugates for modulation of location-specific subtypes of receptors and ion channels | Molokanova, Elena (US) | 2026-02-03 | — | — | US | disclosed |
| US-20240383894-A1 | HETEROBIDENTATE IMIDAZO[1,5-A]PYRIDINE AND IMIDAZO[1,5-A]QUINOLINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME | UNIV RUTGERS (US) | 2024-11-21 | — | — | US | disclosed |
| EP-4452488-A1 | HETEROBIDENTATE IMIDAZO[1,5-A]PYRIDINE AND IMIDAZO[1,5-A]QUINOLINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME | Rutgers, The State University Of New Jersey (US) | 2024-10-30 | — | — | EP | disclosed |
| CN-111278811-B | Aminobenzimidazole derivatives, methods of treating and inhibiting histone deacetylase | 转化药物开发有限责任公司 | 2024-08-23 | — | — | CN | disclosed |
| US-20100248264-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | disclosed |
| WO-2010101649-A2 | SIGMA 1 RECEPTOR INHIBITION AS A NOVEL THERAPEUTICAL APPROACH AGAINST HEPATITIS C VIRUS INFECTION | GASTAMINZA PABLO (US) | 2010-09-10 | — | — | WO | disclosed |
| EP-1773306-A1 | MEDICAMENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Greenpharma (FR) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006018538-A1 | MEDICAMENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | GREENPHARMA (FR) | 2006-02-23 | — | — | WO | disclosed |
| EP-0346791-B1 | 1,2-diarylethylamines for treatment of neurotoxic injury | SEARLE & CO (US) | 1994-04-06 | — | — | EP | disclosed |
| JP-H0236171-A | DIARYLETHYLENEDIAMINE DERIVATIVE AND PHARMACEUTICAL COMBUSTION CONTAINING THE SAME | G D SEARLE & CO | 1990-02-06 | — | — | JP | disclosed |
| EP-0346791-A1 | 1,2-diarylethylamines for treatment of neurotoxic injury | G.D. Searle & Co. (US) | 1989-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355596-A1 | COMPOSITIONS AND METHODS OF USING NMDAR INHIBITORS AND KINASE INHIBITORS TO TREAT LIVER CANCER | GRIN1, GRIN3A, GRIN3B | CYP1A2 4459/4885CYP2C19 4581/4885CYP3A4 4480/4885 |
| US-12539337-B2 | Nanostructure conjugates for modulation of location-specific subtypes of receptors and ion channels | GRIN2B, GRIN2A, GRIN3A | CYP1A2 4734/4885CYP2C19 4666/4885CYP3A4 4582/4885 |
| US-20240383894-A1 | HETEROBIDENTATE IMIDAZO[1,5-A]PYRIDINE AND IMIDAZO[1,5-A]QUINOLINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME | NDC1, NUDC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CYP1A2 940/4885CYP2C19 2262/4885CYP3A4 157/4885 |
| US-12636264-B2 | Methods and materials for diagnosis and treatment of neuronal disorder | PHGDH, PSEN2, PSEN1 | CYP1A2 4495/4885CYP2C19 3842/4885CYP3A4 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.